On January 4, 2019, Ribon Therapeutics, Inc. closed the transaction. The series B round of funding was led by new investor, Novartis Venture Fund, a fund managed by Novartis Venture Funds. The transaction included participation from new investors, Celgene Corporation and Johnson & Johnson Innovation - JJDC, Inc., and existing investors, The Column Group LLC, Deerfield Management Company, L.P., U.S. Venture Partners, Osage University Partners, Takeda Ventures, Inc., and Euclidean Capital LLC.